Inclusion Criteria:

          1. Voluntarily agree to participate by giving written informed consent. (Participation in
             pharmacogenomics testing is optional).

          2. Be ≥18 years of age.

          3. Diagnosis:

               1. Have (1) a histologically or cytologically confirmed diagnosis of squamous-cell
                  carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix, and (2)
                  metastatic, locally advanced, and/or unresectable disease at the time of
                  enrollment. Histologic confirmation of the original primary tumor is required via
                  pathology report.

                  Note: The following cervical tumors are not eligible: minimal deviation/adenoma
                  malignum, gastric type adenocarcinoma, clear cell carcinoma, and mesonephric
                  carcinoma.

               2. Has cervical cancer and has relapsed after a platinum- based treatment (first
                  line) regimen for advanced (recurrent, unresectable, or metastatic) disease;

          4. Measurable Disease

             a) Have measurable disease on imaging based on RECIST version 1.1 by Investigator
             assessments and independent central radiologic review.

             Note: Patients without centrally confirmed measurable disease at baseline will not be
             eligible for this trial.

             Note: Patients must have at least 1 "target lesion" to be used to assess response, as
             defined by RECIST version 1.1. Tumors within a previously irradiated field will be
             designated as "non-target" lesions unless progression is documented, or a biopsy is
             obtained to confirm persistence at least 90 days following completion of radiation
             therapy.

          5. Have a life expectancy of at least 3 months and an Eastern Cooperative Oncology Group
             (ECOG) performance status of 0 or 1.

          6. Have adequate organ function as indicated by the following laboratory values:

               1. Adequate hematological function defined by absolute neutrophil count (ANC) > 1.5
                  x 10^9/L, platelet count > 100 x 10^9/L, and hemoglobin >8 g/dL (without
                  transfusions within 1 week of first dose).

               2. Adequate hepatic function based by a total bilirubin level ≤ 1.5 the
                  institutional upper limit of normal (IULN), aspartate aminotransferase (AST)
                  level ≤ 2.5 x IULN, alanine aminotransferase (ALT) level ≤ 2.5 x IULN, and
                  alkaline phosphatase ≤ 2.5 IULN and albumin ≥3.0 mg/dL.

               3. Adequate renal function defined as creatinine ≤ 1.5 × upper limit of normal (ULN)
                  OR measured or calculated creatinine clearance ≥ 40 mL/minute per Institutional
                  standard. Assessment methods should be recorded.

               4. Adequate coagulation defined by international normalized ratio (INR) or
                  prothrombin time ≤ 1.5 x IULN (unless the patient is receiving anticoagulant
                  therapy); and activated partial thromboplastin time (aPTT) ≤ 1.5 x IULN (unless
                  the patient is receiving anticoagulant therapy)

          7. Has no history of another primary malignancy, with the exception of:

               1. Malignancy treated with curative intent and with no known active disease ≥ 3
                  years before the first dose of study drug and of low potential risk for
                  recurrence.

               2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
                  of disease and superficial bladder cancer.

          8. Patients must provide a sufficient and adequate FFPE tumor tissue sample preferably
             from the most recent biopsy of a tumor lesion, collected either at the time of or
             after the diagnosis of advanced or metastatic disease has been made AND from a site
             not previously irradiated. Archival tumor tissue must be ≤ 3 years old. If no tumor
             tissue is available, a fresh biopsy will be required (See Section 7.2.3.1 for
             details).

             Note: Tissue from core biopsy or excisional biopsy or from resection is required.

          9. Patients must have a negative serum pregnancy test at screening (within 72 hours of
             first dose of study medication) if of childbearing potential or be of non-child
             bearing potential. Non-childbearing potential is defined as (by other than medical
             reasons):

               1. ≥45 years of age and has not had menses for greater than 1 year,

               2. Amenorrheic ≥ 2 years without a hysterectomy and oophorectomy and a
                  follicle-stimulating hormone (FSH) value in the postmenopausal range upon
                  pretrial (screening) evaluation,

               3. History of hysterectomy, oophorectomy or tubal ligation.

               4. Definitive pelvic radiation for the treatment of cervical cancer.

         10. If of childbearing potential, female patients must be willing to use 2 adequate
             barrier methods throughout the study, starting with the screening visit through 120
             days after the last dose of study treatment. Note: Abstinence is acceptable if this is
             the established and preferred contraception for the patient.

         11. Is willing and able to comply with the requirements of the protocol.

        Exclusion Criteria:

        The patient must be excluded from participating in the trial if the patient:

        The patient must be excluded from participating in the trial if the patient:

          1. Is currently participating and receiving study therapy or has participated in a study
             of an investigational agent and received study therapy or used an investigation device
             within 4 weeks of the first dose of treatment.

          2. Has an inadequate washout period prior to first dose of study drug defined as:

               1. Received systemic cytotoxic chemotherapy or biological therapy within 3 weeks
                  before first dose,

               2. Received radiation therapy within 3 weeks before first dose, or

               3. Had major surgery within 4 weeks before first dose.

          3. Has received prior therapy with:

               1. Any antibody/drug targeting T-cell co-regulatory proteins (immune checkpoints)
                  such as anti-PD-1, anti-PD-L1, or anti- cytotoxic T-lymphocyte antigen 4 (CTLA-4)
                  antibodies

               2. More than 1 systemic treatment regimen for the advanced (recurrent, unresectable,
                  or metastatic) cervical cancer for which the patient is considered for the study.

          4. Has persisting toxicity related to prior therapy of National Cancer Institute Common
             Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE) Grade >1 severity.

             Note: Sensory neuropathy or alopecia of Grade ≤2 is acceptable.

          5. Is expected to require any other form of systemic or localized antineoplastic therapy
             while on trial (including maintenance therapy with another agent, radiation therapy,
             and/or surgical resection).

          6. Has known severe hypersensitivity reactions to fully human monoclonal antibodies
             (NCI-CTCAE Grade ≥3), any history of anaphylaxis, or uncontrolled asthma.

          7. Has received systemic corticosteroid therapy ≤ 7 days prior to the first dose of trial
             treatment or receiving any other form of systemic immunosuppressive medication
             (corticosteroid use on study for management of immune-related adverse events (AE),
             and/or a premedication for IV contrast allergies/reactions is allowed). Patients who
             are receiving daily corticosteroid replacement therapy are an exception to this rule.
             Daily prednisone at doses of up to 5 mg or equivalent hydrocortisone dose are examples
             of permitted replacement therapy.

          8. Has a central nervous system (CNS) tumor, metastasis(es), and/or carcinomatous
             meningitis identified either on the baseline brain imaging obtained during the
             screening period OR identified prior to consent.

             Note: Patients with history of brain metastases that have been treated may participate
             provided they show evidence of stable supra-tentorial lesions at screening (based on 2
             sets of brain images, performed ≥ 4 weeks apart, and obtained after the brain
             metastases treatment). In addition, any neurologic symptoms that developed either as a
             result of the brain metastases or their treatment must have resolved or be minimal and
             be expected as sequelae from treated lesions. For individuals who received steroids as
             part of brain metastases treatment, steroids must be discontinued ≥ 7 days prior to
             first dose of study drug.

          9. Has active or history of autoimmune disease that has required immunosuppressive
             systemic treatment within 2 years of the start of trial treatment (i.e. with use of
             disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement
             therapy (i.e., thyroxine, insulin, or physiologic corticosteroid replacement therapy
             for adrenal or pituitary insufficiency, etc.) is not considered a form of
             immunosuppressive systemic treatment.

             Note: Patients with diabetes type 1, vitiligo, psoriasis, hypo-, or hyperthyroid
             disease not requiring immunosuppressive treatment are eligible.

         10. Has had an allogeneic tissue/solid organ transplant.

         11. Has or had interstitial lung disease (ILD) OR has had a history of pneumonitis that
             has required oral or IV corticosteroids

             .

         12. Has an active infection requiring intravenous (IV) systemic therapy.

         13. Has known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

         14. Has known active Hepatitis B (HBV), Hepatitis C (HCV), or tuberculosis. Active
             Hepatitis B is defined as a known positive HBsAg result. Active Hepatitis C is defined
             by a known positive Hep C Ab result and known quantitative HCV ribonucleic acid (RNA)
             results greater than the lower limits of detection of the assay.

         15. Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular
             accident/stroke or myocardial infarction within 6 months of enrollment, unstable
             angina, congestive heart failure (New York Heart Association class ≥II), or serious
             uncontrolled cardiac arrhythmia requiring medication.

         16. Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the patient's
             participation for the full duration of the trial, or is not in the best interest of
             the patient to participate, in the opinion of the treating investigator.

         17. Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

         18. Is, at the time of signing informed consent, a regular user (including "recreational
             use") of any illicit drugs or had a recent history (within the last year) of substance
             abuse (including alcohol). Medicinal marijuana use is not considered "illicit" and is
             allowed to be utilized prior to and during enrollment.

         19. Is legally incapacitated or has limited legal capacity.

         20. Is pregnant or breastfeeding or expecting to conceive within the projected duration of
             the trial, starting with the screening visit through 120 days after the last dose of
             the study drug